HRCM
KRYS icon

Hood River Capital Management’s Krystal Biotech KRYS Stock Holding History

Hood River Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160M Buy
619,586
+6,284
+1% +$1.67M 1.6% 13
2025
Q4 		$151M Buy
613,302
+6,356
+1% +$1.34M 1.66% 11
2025
Q3 		$107M Buy
606,946
+73,923
+14% +$11.1M 1.27% 24
2025
Q2 		$73.3M Buy
533,023
+8,379
+2% +$1.23M 1.02% 35
2025
Q1 		$94.6M Buy
524,644
+11,918
+2% +$2M 1.61% 12
2024
Q4 		$80.3M Buy
512,726
+10,622
+2% +$1.88M 1.19% 28
2024
Q3 		$91.4M Sell
502,104
-18,989
-4% -$3.66M 1.48% 17
2024
Q2 		$95.7M Buy
521,093
+25,507
+5% +$4.28M 1.98% 9
2024
Q1 		$88.2M Buy
495,586
+37,073
+8% +$5.15M 1.97% 11
2023
Q4 		$56.9M Sell
458,513
-1,976
-0.4% -$219K 1.56% 18
2023
Q3 		$53.4M Buy
460,489
+8,033
+2% +$980K 1.71% 15
2023
Q2 		$53.1M Buy
452,456
+5,063
+1% +$517K 1.58% 22
2023
Q1 		$35.8M Buy
447,393
+20,514
+5% +$1.61M 1.16% 38
2022
Q4 		$33.8M Buy
426,879
+10,123
+2% +$751K 1.23% 32
2022
Q3 		$29M Buy
416,756
+7,745
+2% +$560K 1.11% 33
2022
Q2 		$26.9M Buy
409,011
+24,201
+6% +$1.51M 1.07% 36
2022
Q1 		$25.6M Buy
384,810
+159,083
+70% +$9.93M 0.85% 43
2021
Q4 		$15.8M Sell
225,727
-174
-0.1% -$10.1K 0.47% 68
2021
Q3 		$11.8M Sell
225,901
-8,866
-4% -$525K 0.36% 76
2021
Q2 		$16M Sell
234,767
-3,115
-1% -$217K 0.48% 73
2021
Q1 		$18.3M Sell
237,882
-23,240
-9% -$1.69M 0.59% 68
2020
Q4 		$15.7M Buy
261,122
+3,919
+2% +$196K 0.52% 77
2020
Q3 		$11.1M Sell
257,203
-25,008
-9% -$1.09M 0.48% 77
2020
Q2 		$11.7M Buy
+282,211
New +$13.6M 0.52% 76

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hood River Capital Management's KRYS Position: Q1 2026 in Review

Hood River Capital Management increased its Krystal Biotech (KRYS) stake by 1% in Q1 2026, buying an estimated $1.67M and bringing the position to 619,586 shares worth $160M. The position accounts for 1.6% of the portfolio, ranked #13.

Hood River Capital Management first reported a position in KRYS in Q2 2020 and has held it in 24 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Hood River Capital Management held 619,586 shares of Krystal Biotech worth $160M as of Q1 2026.
  • Hood River Capital Management bought 6,284 Krystal Biotech shares in Q1 2026, an estimated $1.67M.
  • Krystal Biotech made up 1.6% of Hood River Capital Management's portfolio in Q1 2026, its #13 holding.
  • Hood River Capital Management first reported a position in Krystal Biotech in Q2 2020 and has held it in 24 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Hood River Capital Management's 13F filing for Q1 2026, filed 15 May 2026.